← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Lappe Mark
Chief Executive Officer | Officer
Identity: SEC owner CIK matched through an unambiguous cached owner-name crosswalk · Reporting-owner CIK: 0001366074
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 3
- Average purchase
- $1.5M
- Median purchase
- $998.8K
- Gross purchase value
- $4.5M
Companies: Inhibrx Biosciences, Inc.
3 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-10-14 | Inhibrx Biosciences, Inc. | INBX | Chief Executive Officer | Officer | $840.4K | Open filing |
| 2026-09-28 | Inhibrx Biosciences, Inc. | INBX | Chief Executive Officer | Officer | $998.8K | Open filing |
| 2026-09-08 | Inhibrx Biosciences, Inc. | INBX | Chief Executive Officer | Officer | $2.6M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 100.0% (2/2) | 0.0% (0/2) | -7.4% | -7.4% | -8.2% |
| 20D | 1Small Sample | 100.0% (1/1) | 0.0% (0/1) | -20.3% | -20.3% | -20.3% |
| 60D | 0No Data | Awaiting maturity | — | — | — | — |
| 120D | 0No Data | Awaiting maturity | — | — | — | — |
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ $100k
- 3/3
- Cluster buying · 15D
- 2/3
- Buying the dip
- 2/3
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.